ProQR Therapeutics N.V. (NASDAQ:PRQR) Stock Has Average Price Target of $7.60

Shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) have been assigned an average rating of “Moderate Buy” from the eight analysts that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $7.60.

A number of equities research analysts have recently issued reports on the stock. JonesTrading cut their price objective on shares of ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Friday, June 26th. Chardan Capital reaffirmed a “buy” rating and set a $3.00 target price on shares of ProQR Therapeutics in a report on Thursday, October 1st. Weiss Ratings upgraded shares of ProQR Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 14th. Citigroup reissued a “market outperform” rating on shares of ProQR Therapeutics in a research note on Thursday, October 1st. Finally, HC Wainwright lowered their price target on shares of ProQR Therapeutics to $8.00 and set a “buy” rating for the company in a research note on Thursday, October 1st.

ProQR Therapeutics Stock Up 5.3%

Shares of PRQR opened at $1.38 on Friday. The stock has a 50 day simple moving average of $1.87 and a two-hundred day simple moving average of $1.75. ProQR Therapeutics has a 1 year low of $1.30 and a 1 year high of $3.10.

ProQR Therapeutics (NASDAQ:PRQR) last issued its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.04. The business had revenue of $10.00 million for the quarter, compared to analysts’ expectations of $4.56 million. ProQR Therapeutics had a negative net margin of 223.51% and a negative return on equity of 73.83%. On average, equities research analysts forecast that ProQR Therapeutics will post -0.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. RFG Advisory LLC lifted its stake in shares of ProQR Therapeutics by 236.8% in the 2nd quarter. RFG Advisory LLC now owns 64,000 shares of the biopharmaceutical company’s stock valued at $119,000 after acquiring an additional 45,000 shares during the last quarter. Axiom Investment Management LLC bought a new position in ProQR Therapeutics during the 1st quarter worth approximately $53,000. Bank of America Corp DE grew its position in ProQR Therapeutics by 6.4% during the 1st quarter. Bank of America Corp DE now owns 185,110 shares of the biopharmaceutical company’s stock worth $300,000 after acquiring an additional 11,186 shares during the last quarter. Finally, Walleye Capital LLC grew its position in ProQR Therapeutics by 2.7% during the 1st quarter. Walleye Capital LLC now owns 607,529 shares of the biopharmaceutical company’s stock worth $984,000 after acquiring an additional 15,744 shares during the last quarter. Hedge funds and other institutional investors own 32.65% of the company’s stock.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a biotechnology company focused on developing RNA-based medicines for genetic diseases. The company’s research is centered on using RNA therapies to correct or modify disease-causing genetic information, with the goal of addressing conditions that may not be effectively treated through conventional drug-development approaches.

ProQR’s technology portfolio includes Axiomer, an RNA-editing platform designed to make precise changes to RNA inside cells. The company has also developed investigational therapies for inherited retinal diseases and other genetic disorders.